Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 6, 2017, Pages 1136-1142

  Fox, D Steven ^a   McGinnis, Justin J ^b,c   Tonnu Mihara, Ivy Q ^c   McCombs, Jeffrey S ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

direct antiviral agents; hepatitis C; ledipasvir; ombitasvir; simeprevir

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SIMEPREVIR PLUS SOFOSBUVIR; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VETERANS HEALTH; VIRUS LOAD; ANCESTRY GROUP; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DATA BASE; GOVERNMENT; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; CONTINENTAL POPULATION GROUPS; DATABASES AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; YOUNG ADULT;

EID: 85020077621     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13652     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. U.S. 2014 Surveillance Data for Viral Hepatitis. Statistics & Surveillance. Division of Viral Hepatitis, 2016. [cdc.gov/hepatitis/statistics/2014surveillance/pdfs/2014hepsurveillancerpt.pdf].
2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29: 74–81.
3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci. 2006; 3: 47–52.
4. Seeff LB. The history of the "natural history" of hepatitis C (1968–2009). Liver Int. 2009; 29: 89–99.
5. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin. Infect. Dis. 2012; 55: S3–S9.
6. Smith BD, Morgan RL, Beckett GA et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm. Rep. 2012; 61: 1–32.
7. Denniston MM, Jiles RB, Drobeniuc J, Klevens M, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 2014; 160: 293–300.
8. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005; 41: 88–96.
9. Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384: 1756–1765.
10. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370: 1889–1898.
11. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014; 370: 1483–1493.
12. Kowdley KV, Gordon SG, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370: 1879–1888.
13. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370: 1594–1603.
14. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370: 1604–1614.
15. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 2014; 370: 1973–1982.
16. Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE et al. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int. 2016; 36: 651–658.
17. Saxena V, Koraishy FM, Sise ME et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016; 36: 807–816.
18. Backus LI, Belperio SP, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir +/− ribavirin vs. ombitasvirparitaprevir/ritonavir + dasabuvir +/− ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment. Pharmacol. Ther. 2016; 44: 400–410.
19. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology 2016; 64: 405–414.
20. Ioannou GN, Beste LA, Chang MF et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir retimens for the treatment of patients with hepatitis C in the veterans affairs national healthcare system. Gastroenterology 2016; 151: 457–471. e5.
21. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–36.
22. Tonnu-Mihara I, Matsuda T, McCombs JS et al. Five laboratory tests predict patient risk and treatment response in hepatitis C: veterans affairs sata from 1999–2010. Univers. J. Med. Sci. 2015; 4: 10–20.
23. Matsuda T, McCombs JS, Tonnu-Mihara I, McGinnis JJ, Fox DS. The impact of delayed hepatitis C viral load suppression on patient risk: historical evidence from the veterans administration. Forum Health Econ. Pol. 2016; 19: 333–351.
24. Fox DS, McCombs JS. Optimizing HCV treatment – Moving beyond the cost conundrum. J. Hepatol. 2016; 65: 222–225.
25. Van Nuys K, Brookmeyer R, Chou JW, Dreyfus D, Goldman DP. Broad hepatitis C treatment scenarios return substantial health gains, but capacity is a concern. Health Aff. 2015; 34: 1666–1674.
26. Aqel BA, Pungpapong S, Leise M et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62: 1004–1012.
27. Pungpapong S, Aqel B, Leise M et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015 Jun 1; 61: 1880–1886.
28. Steinebrunner N, Sprinzl MF, Zimmermann T et al. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort. BMC Gastroenterol. 2015; 15: 1.
29. Yoshida EM, Sulkowski MS, Gane EJ et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015; 61: 41–45.
30. Chen J, Florian J, Carter W et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450–1455.